SCHEMBL5586815

SCHEMBL5586815

CCc1cc(O)c(O)c(CC)c1CC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.43
ALOX12 P18054 1/20 0.43
GABRA1 P14867 1/20 0.41
GABRB2 P47870 1/20 0.41
BACE1 P56817 1/20 0.38
PTPN1 P18031 2/20 0.38
PRKCE Q02156 3/20 0.38
MEN1 O00255 3/20 0.38
ALDH1A1 P00352 3/20 0.38
MAPT P10636 3/20 0.38
KMT2A Q03164 3/20 0.38
TDP1 Q9NUW8 3/20 0.38
APEX1 P27695 2/20 0.38
RECQL P46063 2/20 0.38
MYLK Q15746 2/20 0.38
PRKCG P05129 1/20 0.38
PRKCA P17252 1/20 0.38
CA1 P00915 2/20 0.37
CA2 P00918 2/20 0.37
KDM4E B2RXH2 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5678590 0.87 PGAM1 (0.42) ALOX15ALOX12GABRA1GABRB2BACE1
SCHEMBL5676259 0.87 PGAM1 (0.42) ALOX15ALOX12GABRA1GABRB2BACE1
SCHEMBL11883784 0.86 ALOX15 (0.43) ALOX15ALOX12GABRA1GABRB2BACE1
SCHEMBL1179824 0.83 ALOX15 (0.45) ALOX15ALOX12GABRA1GABRB2BACE1
SCHEMBL294103 0.83 ALOX15 (0.45) ALOX15ALOX12GABRA1GABRB2BACE1
SCHEMBL25328782 0.83 GABRA1 (0.42) ALOX15ALOX12GABRA1GABRB2BACE1
SCHEMBL31092542 0.83 GABRA1 (0.42) ALOX15ALOX12GABRA1GABRB2BACE1
SCHEMBL30989135 0.83 ALOX15 (0.45) ALOX15ALOX12GABRA1GABRB2BACE1
SCHEMBL5680402 0.81 TYR (0.47) ALOX15MEN1ALDH1A1MAPTKMT2A
SCHEMBL1760472 0.81 ALOX15 (0.43) ALOX15ALOX12GABRA1GABRB2BACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107167978-B Blue phase liquid crystal display, method of manufacturing the same, and chiral material used therefor 友达光电股份有限公司 2020-09-18 CN disclosed
US-7247687-B2 Late transition metal catalysts for olefin polymerization and oligomerization EXXONMOBIL CHEMICAL PATENTS INC. (US) 2007-07-24 US disclosed
EP-1521758-B1 LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION EXXONMOBIL CHEM PATENTS INC (US) 2006-05-24 EP disclosed
US-20060047094-A1 Late transition metal catalysts for olefin polymerization and oligomerization EXXONMOBIL CHEMICAL PATENTS INC. 2006-03-02 US disclosed
EP-1521758-A1 LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION Exxonmobil Chemical Patents Inc. (US) 2005-04-13 EP disclosed
WO-2004007509-A1 LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION EXXONMOBIL CHEMICAL PATENTS INC. (US) 2004-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060047094-A1 Late transition metal catalysts for olefin polymerization and oligomerization MLX, LOX, LMTK3 ALOX15 76/4885ALOX12 50/4885GABRA1 3688/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.